Preliminary FDA review finds no link between suicidal thoughts and weight-loss drugs

Preliminary results from an ongoing FDA investigation found no evidence that weight-loss drugs cause suicidal ideations and aspirations, although the agency said it cannot rule out a risk entirely.
In a quarterly report released on Jan. 2, the FDA revealed it was investigating potential safety signals of popular weight-loss medications like Ozempic (semaglutide, Novo Nordisk), Wegovy (semaglutide, Novo Nordisk) Mounjaro (tirzepatide, Eli Lilly), Zepbound (tirzepatide, Eli Lilly) and Saxenda (liraglutide, Novo Nordisk). Semaglutide and liraglutide are both GLP-1 receptor agonists, whereas

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart